ElieGDibMD, MS, FACP

Hematologic Oncology

Associate Director - Hematology Oncology Training. St Joseph Mercy hospital. Adjunct Faculty Lecturer, Johns Hopkins University

Join to view full profile

Dr. Dib is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dib's full profile

Already have an account?

Office
5303 Elliott Dr
Ypsilanti, MI 48197
Phone+1 734-712-1000

Fax+1 734-712-1012

Education & Training

Johns Hopkins University Advanced Academic ProgramsMaster in Science, Individualized Genomics and Health, 2019 - 2022
Harvard Medical SchoolPost-Graduate Program, Cancer Biology & Therapeutics: High Impact Cancer Research, 2018 - 2019
University of RochesterFellowship, Hematology and Medical Oncology, 2003 - 2006

Certifications & Licensure

MI State Medical License 2014 - 2027
NY State Medical License 2005 - 2027
SD State Medical License Active through 2027
MA State Medical License 2022 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer Start of enrollment: 2017 Jun 21
Active, not recruiting
Phase 3
Oxybutynin Chloride in Managing Hot Flashes Start of enrollment: 2016 Dec 09
Completed
Phase 3
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Start of enrollment: 2017 Feb 24
Active, not recruiting
Phase 3
Electronic Patient Reporting of Symptoms During Cancer Treatment Start of enrollment: 2017 Oct 30
Active, not recruiting
Not Applicable
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer Start of enrollment: 2018 Aug 15
Active, not recruiting
Phase 2
Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2019 Jan 31
Active, not recruiting
Phase 3
Supportive Care Service Availability for Cancer Caregivers in Community Oncology Practices Start of enrollment: 2018 Dec 10
Completed
Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting Start of enrollment: 2019 Jan 08
Withdrawn
Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer Start of enrollment: 2019 Feb 15
Terminated
Phase 3
Assessment of Financial Difficulty in Participants With Chronic Lymphocytic Leukemia and Multiple Myeloma Start of enrollment: 2019 Mar 15
Completed
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors Start of enrollment: 2019 Jun 27
Recruiting
Phase 3
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer Start of enrollment: 2019 Aug 09
Active, not recruiting
Phase 2
Learning Collaborative Vs Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer Start of enrollment: 2021 Jul 06
Enrolling by invitation
Not Applicable
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Start of enrollment: 2020 Mar 16
Active, not recruiting
Phase 2
Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors Start of enrollment: 2020 Feb 10
Completed
Phase 2
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects Start of enrollment: 2020 Jan 31
Recruiting
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM Start of enrollment: 2020 Oct 21
Active, not recruiting
Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas Start of enrollment: 2015 Aug 01
Recruiting
Phase 2
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy Start of enrollment: 2020 Dec 10
Active, not recruiting
Phase 3
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Start of enrollment: 2020 Sep 01
Active, not recruiting
Phase 2, Phase 3
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Start of enrollment: 2015 Aug 17
Active, not recruiting
Phase 2
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker Start of enrollment: 2020 Jul 20
Active, not recruiting
Phase 2
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer Start of enrollment: 2020 Jul 13
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Exploring geriatric assessment-driven rehabilitation referral patterns and its influence on functional outcomes and survival in older adults with advanced cancer.
Rachelle Brick, Marielle Jensen-Battaglia, Brennan P Streck, Lindsey Page, Rachael Tylock
Journal of the American Geriatrics Society. 2025-01-01
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Timothy L Cannon, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vi K Chiu
Journal of Clinical Oncology. 2024-09-20
Granulomatous hepatitis: Is it bugs, drugs, or other untoward culprits?
Neil Shah, Elie G Dib, Nora Joseph, Robert J Fontana
Clinical Liver Disease. 2024-04-15

Journal Articles

Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamou...
Steven F. Powell, Miroslaw Mazurczak, Elie G. Dib, Jonathon S. Bleeker, Louis H. Geeraerts, Matthew Tinguely, Michele M. Lohr, Steven C. McGraw, Ashley W. Jensen, Chri..., Investigational New Drugs, 3/21/2022
Book review: Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management
Dib EG, Leukemia Research. 2004 Sept; 28 (9): 995
Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study
Steven F. Powell, Elie G. Dib, Jonathan S. Bleeker, Michael D. Keppen, Miroslaw Mazurczak, Keely M. Hack, Mark M. Gitau, Preston D. Steen, Shelby A. Terstriep, John Re..., JCO Precision Oncology, 2018

Abstracts/Posters

Using bioinformatic tools to examine similarities between human PDL-1 protein and common tobacco (Nicotiana tabacum)
Elie Dib, Nichiolas Hill, Jessica Wollard, Ji Woon Yoo, Joe Dib, Anutosh Ganguly, Clifford Cho, J Clin Oncol 38, 2020 (suppl 5; abstr 70). 2020 ASCO-SITC Clinical Immuno-Oncology Symposium. Poster Presentation
Palbociclib (P) in patients (Pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (...
Eugene R Ahn, Pam K. Mangat, Elizabeth Garrett-Mayer, Susan Halabi, Elie G. Dib, Daniel Ernest Haggstrom, Kathryn B. Alguire, Ricardo H. Alvarez, Carmen Julia Calfa, T..., J Clin Oncol 37, 2019 (suppl; abstr 9041). 2019 ASCO Annual Meeting. Abstract Number: 9041
Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
Elie G Dib, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
Elie G Dib, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Association of Frailty with Emotional Health of Older Patients with Advanced Cancer: A University of Rochester NCI Community Oncology Research Program Geriatric Assess...
Nikesha Gilmore, Huiwen Xu, Eva Culakova, Marie Flannery, Ronak Amir Sardari, Megan Wells, Valerie Aarne Grossman, Mark A. O'Rourke, Nicholas J Vogelzang, Elie G. Dib,..., Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO), San Francisco, CA, June 2019, 2019
The relationships between geriatric impairments, symptom severity, and quality of life in 342 older adults with advanced cancer: a University of Rochester NCI Communit...
M. Flannery, E. Culakova, H. Xu, K. P. Loh, M. Wells, J. Giguere, A. Conlin, E. Dib, P. Duberstein, W. Dale, S. Mohile, Oral Presentation: Society of International Geriatric Oncology (SIOG) meeting November 2017. Abstract O23., 2017
The impact of geriatric assessment measures on caregiver emotional health: data from a multicenter geriatric assessment (GA) study in the University of Rochester NCI C...
S. Mohile, H. Xu, E. Culakova, B. Canin, F. Marie, N. Gilmore, C. Kamen, A. Hurria, W. Dale, C. Heckler, N. Vogelzang, M. Thomas, E. Dib, M. Karen, P. Duberstein., Oral Presentation: Society of International Geriatric Oncology (SIOG) meeting November 2017. Abstract O24., 2017
Optimizing Genotype Matched Clinical Trial (GMCT) accrual in a community oncology program (COP).
Steven Francis Powell, Elie G. Dib, Jonathan Scott Bleeker, Michael D. Keppen, Miroslaw Mazurczak, Keely Marie Hack, Mark Mutuota Gitau, Preston D. Steen, Shelby A. Te..., J Clin Oncol 34, 2016 (suppl; abstr e18036), 2016
Preliminary results of a phase II randomized trial of DCA (Dichloroacetate) in combination with cisplatin and definitive radiation in stage III-IV squamous cell carcin...
Steven F Powell, MD, William C Spanos, MD, Andrew Terrell, MD, Miroslaw Mazurczak, MD, Michael Keppen, MD, Sana Jeffreys, MD, Elie Dib, MD, Mark Gitau, MD, Keely Hack,..., ct from the 2015 American Head & Neck Society Translational Research meeting and annual meeting: April 21-22, 2015: Abstract S008, 2015
High Incidence of Thromboembolic Complications and PF4 Positivity in Patients with Ventricular Assist Devices
Brandon J. McMahon, MD, Jainulabdeen J. Ifthikharuddin, MD, Elie Dib, MD, Leway Chen, MD, Charles W. Francis, MD and Todd H. Massey, MD, Blood (ASH Annual Meeting Abstracts) 2006 108: Abstract 4083, 2006
Use of colony stimulating Factors (G-CSF and GM-CSF) after allogeneic Hematopoietic stem cell transplantation in adult patients: a meta-analysis of published studies
Komrokji RS, Dib EG, Liesveld JL, Phillips GL, Lyman GH., Proceedings of the American Society of Clinical Oncology 23: page 590, 2004 (abstr 6638), 2004
Update of a phase I/II trial of carboplatin/gemcitabine plus escalating doses of celecoxib for first-line treatment of stage IIIB/IV non-small cell lung cancer (NSCLC).
Burton JD, Badine E, El-Sayah D, Dib EG, Forte F, Terjanian T, Odaimi M, Vesoniaraki M, Friscia P, Lowry J., Proceedings of the American Society of Clinical Oncology 23: page 697, 2004 (abstr 7339), 2004
Join now to see all